Canaccord Genuity Starts BioXcel Therapeutics (BTAI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UBS Starts BioXcel Therapeutics (BTAI) at Buy
April 2, 2018 6:51 AM EDTUBS initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Buy rating and a price target of $18.00.
For an analyst ratings summary and ratings history on BioXcel Therapeutics click here. For more ratings news on BioXcel Therapeutics click here.
Shares of BioXcel Therapeutics closed at $10.24 Friday.
... MoreBarclays Starts BioXcel Therapeutics (BTAI) at Overweight
April 2, 2018 4:26 AM EDTBarclays initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Overweight rating and a price target of $15.00.
Analyst Geoff Meacham says the company is a unique play in both neurology and oncology as well as AI and sees good potential for shares... More
BMO Capital Starts BioXcel Therapeutics (BTAI) at Outperform
April 2, 2018 4:23 AM EDTBMO Capital initiates coverage on BioXcel Therapeutics (NASDAQ: BTAI) with a Outperform rating and a price target of $23.00.
Analyst Do Kim comments "We believe BXCL501's sublingual formulation and favorable efficacy/safety profile will enable BioXcel to consolidate a highly fragmented market in... More
